Clinical Trial Update: Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on HLA Class I haplotype-mismatched natural killer cell infusions for hematologic cancers, including lymphoma, multiple myeloma, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• Natural Killer Cell Infusions (natural killer cells)

Snippet

Sponsor: Tufts Medical Center | Conditions: Lymphoma, Myeloma | Phase 1 | Status: COMPLETED